Literature DB >> 20390425

Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Stamatios Theocharis1, Jerzy Klijanienko, Constantinos Giaginis, Jose Rodriguez, Thomas Jouffroy, Angelique Girod, Daniel Point, Gerasimos Tsourouflis, Xavier Satre-Garau.   

Abstract

PURPOSE: Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-activated transcription factor, implicated in various aspects of cancer biology, such as differentiation, proliferation, invasion and angiogenesis. The present study aimed to evaluate the clinical significance of PPAR-γ in mobile tongue squamous cell carcinoma (SCC).
METHODS: PPAR-γ protein expression was assessed immunohistochemically on 49 mobile tongue SCC tissue samples obtained from an equal number of patients. PPAR-γ expression and intensity of immunostaining were statistically analyzed in relation with clinicopathological characteristics, mitotic index and patients' survival.
RESULTS: Elevated PPAR-γ expression was more frequently observed in patients with reduced depth of invasion (P = 0.0111). Moderate/intense PPAR-γ staining intensity was more frequently observed in patients with no evidence of muscular infiltration (P = 0.0229) and reduced depth of invasion (P = 0.0176). Mobile tongue SCC patients presenting enhanced PPAR-γ expression had significantly longer overall and disease-free survival times compared to those with low PPAR-γ expression (log-rank test, P = 0.0162 and P = 0.0114, respectively).
CONCLUSIONS: PPAR-γ immunoreactivity in mobile tongue SCC was correlated with clinicopathological characteristics crucial for patients' management and prognosis. PPAR-γ may be considered as a useful prognostic marker in mobile tongue SCC and a potential therapeutic target for tongue cancer chemoprevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20390425     DOI: 10.1007/s00432-010-0882-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  43 in total

1.  Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years.

Authors:  Caroline H Shiboski; Brian L Schmidt; Richard C K Jordan
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

2.  Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases.

Authors:  Perkins Mukunyadzi; Lingbao Ai; Didier Portilla; E Leon Barnes; Chun-Yang Fan
Journal:  Mod Pathol       Date:  2003-12       Impact factor: 7.842

3.  Prognostic factors in the surgical treatment of patients with oral carcinoma.

Authors:  Rajan S Patel; Jonathan R Clark; Richard Dirven; Rebecca Wyten; Kan Gao; Christopher J O'Brien
Journal:  ANZ J Surg       Date:  2009 Jan-Feb       Impact factor: 1.872

Review 4.  Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury.

Authors:  Costas Giaginis; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

5.  Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer.

Authors:  Yukio Terashita; Hidefumi Sasaki; Nobuhiro Haruki; Tadashi Nishiwaki; Hideyuki Ishiguro; Yasuyuki Shibata; Junzo Kudo; Shigeru Konishi; Joji Kato; Hiroshi Koyama; Masahiro Kimura; Atsushi Sato; Noriyuki Shinoda; Yoshiyuki Kuwabara; Yoshitaka Fujii
Journal:  Jpn J Clin Oncol       Date:  2002-07       Impact factor: 3.019

6.  Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival.

Authors:  Stamatios Theocharis; Costas Giaginis; Aikaterini Parasi; Alexandra Margeli; John Kakisis; Emmanuel Agapitos; Gregorios Kouraklis
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

Review 7.  Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.

Authors:  Frank Ondrey
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

8.  Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.

Authors:  G Y Zhang; N Ahmed; C Riley; K Oliva; G Barker; M A Quinn; G E Rice
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

9.  Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis.

Authors:  Shuji Ogino; Kaori Shima; Yoshifumi Baba; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Li Chen; Saori Toyoda; Gregory J Kirkner; Y Lynn Wang; Edward L Giovannucci; Charles S Fuchs
Journal:  Gastroenterology       Date:  2008-12-24       Impact factor: 33.883

10.  Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma.

Authors:  D Wangsa; M Ryott; E Avall-Lundqvist; F Petersson; G Elmberger; J Luo; T Ried; G Auer; E Munck-Wikland
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more
  12 in total

1.  Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Nikolaos Tsoukalas; Ioannis Sfiniadakis; Nikolaos Kavantzas; Emmanuel Agapitos; Efstratios Patsouris; Stamatios Theocharis
Journal:  Tumour Biol       Date:  2014-09-25

2.  Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies.

Authors:  Mutsuko Omatsu; Toshiaki Kunimura; Tetsuya Mikogami; Shigeharu Hamatani; Akira Shiokawa; Atsuko Masunaga; Akihiko Kitami; Takashi Suzuki; Mitsutaka Kadokura; Toshio Morohoshi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-10-03

3.  Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer.

Authors:  Joanna M Poczobutt; Subhajyoti De; Vinod K Yadav; Teresa T Nguyen; Howard Li; Trisha R Sippel; Mary C M Weiser-Evans; Raphael A Nemenoff
Journal:  J Immunol       Date:  2016-02-12       Impact factor: 5.422

Review 4.  PPARγ in head and neck cancer prevention.

Authors:  Mauricio Burotto; Eva Szabo
Journal:  Oral Oncol       Date:  2014-01-13       Impact factor: 5.337

5.  Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.

Authors:  Stamatios Theocharis; Constantinos Giaginis; Paraskevi Alexandrou; Jose Rodriguez; Jason Tasoulas; Eugene Danas; Efstratios Patsouris; Jerzy Klijanienko
Journal:  Tumour Biol       Date:  2015-10-12

6.  Compartment-specific activation of PPARγ governs breast cancer tumor growth, via metabolic reprogramming and symbiosis.

Authors:  Paola Avena; Wanda Anselmo; Diana Whitaker-Menezes; Chenguang Wang; Richard G Pestell; Rebecca S Lamb; James Hulit; Ivan Casaburi; Sebastiano Andò; Ubaldo E Martinez-Outschoorn; Michael P Lisanti; Federica Sotgia
Journal:  Cell Cycle       Date:  2013-04-10       Impact factor: 4.534

7.  Differential expression of fatty acid-binding proteins and pathological implications in the progression of tongue carcinoma.

Authors:  Yoshito Ohyama; Yukihiro Kawamoto; Tadashige Chiba; Kentaro Kikuchi; Hideaki Sakashita; Kazushi Imai
Journal:  Mol Clin Oncol       Date:  2013-10-03

Review 8.  PPAR gamma, bioactive lipids, and cancer progression.

Authors:  Gregory T Robbins; Daotai Nie
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

Review 9.  Chemotherapy and chemoprevention by thiazolidinediones.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

10.  A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.

Authors:  Ling-Ling Sun; Jian-Yi Wu; Zhi-Yong Wu; Jin-Hui Shen; Xiu-E Xu; Bo Chen; Shao-Hong Wang; En-Min Li; Li-Yan Xu
Journal:  Int J Cancer       Date:  2014-09-24       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.